Among those with T2D, individuals in this genetic subtype had lower HbA1c, and were less likely to be prescribed T2D medication, indicating they may require less treatment to maintain glucose homeostasis, and IGF2R and MAS1 variants may contribute to this phenotype. This evidence concerns the gene IGF2R and type 2 diabetes mellitus.